Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Leveraging the Therapeutic Benefits of Transcranial Direct Current Stimulation to Treat Chemotherapy-related Chronic Pain and Psycho-cognitive Comorbidities in Cancer Survivors

NCT07912775 is registered in ClinicalTrials.gov with Instituto de investigación e innovación biomédica de Cádiz as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07912775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Leveraging the Therapeutic Benefits of Transcranial Direct Current Stimulation to Treat Chemotherapy-related Chronic Pain and Psycho-cognitive Comorbidities in Cancer Survivors
Lead sponsor
Instituto de investigación e innovación biomédica de Cádiz
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2028
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, cancer survivors, chemotherapy-related chronic pain, chronic pain, cognitive dysfunction, depression, neuropathic pain

Arms

As registered; 2 arms.

  • Active tDCS ExperimentalActive tDCS with Sternberg task

    Phase I (acute, double-blind): 5 consecutive daily sessions of active tDCS (2 mA, 20 minutes, 30-second ramp-up and ramp-down) combined with the Sternberg working-memory task (10 minutes at rest, then 10 minutes performing the task). Responders (at least 2-point reduction on the pain VAS from baseline) continue to Phase III (maintenance, open-label): active tDCS with the same scheme twice a week for up to 2 months.

  • Sham tDCS Sham comparatorSham tDCS with Sternberg task

    Phase I (acute, double-blind): 5 consecutive daily sessions of sham tDCS (brief ramp-up and ramp-down at the beginning and end of the session, without sustained stimulation) combined with the Sternberg working-memory task (10 minutes at rest, then 10 minutes performing the task). Non-responders then receive Phase II (open-label crossover): 5 consecutive daily sessions of active tDCS. Responders, after Phase I or Phase II, continue to Phase III (maintenance, open-label): active tDCS twice a week for up to 2 months.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in pain intensity (Visual Analogue Scale, VAS) after the acute phase Baseline (T0) and after the acute phase at 1 week (T1)

    Change from baseline in pain intensity measured with the Visual Analogue Scale (VAS), comparing active tDCS with sham tDCS. Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate a worse outcome. Responders are defined as participants with a reduction of at least 2 points from baseline.

Lead sponsor's other trials

Instituto de investigación e innovación biomédica de Cádiz, most recent start first.

Similar trials

Same condition (Neuralgia) and phase, most recent start first.